NASDAQ: ABUS
Arbutus Biopharma Corp
Healthcare · Biotechnology
After hours: $4.58(-1.13%) · as of 7:34 PM ET
Market Cap
$914.60M
52w High
$5.38
52w Low
$3.31
P/E
5.62
Volume
794.83K
Outstanding Shares
197.54M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 36.18% over the last year. Revenue grew 2,889.93% over the trailing twelve months. Operating margin moved from -1,430.8% to 80.79%. Free cash flow grew 41.8% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 3rd percentile of their historical P/S range.
What would invalidate this read
Operating margin is at 80.79%. Revenue grew 2,889.93% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Valuation
Stock splits
Every 5 shares became 1
Profitability & growth
Analyst consensus
8
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q3 FY26 · EPS est -$0.02 · Revenue est $700K
View